A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers-Reference-Cited by-同舟云学术

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

Published:2021-01 Issue:1 Volume:160 Page:71-76
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Rubinstein Maria M.,Grisham Rachel N.,Cadoo Karen,Kyi Chrisann,Tew William P.,Friedman Claire F.,O'Cearbhaill Roisin E.,Zamarin Dmitriy,Zhou Qin,Iasonos Alexia,Nikolovski Ines,Xu Hongmei,Soldan Krysten N.,Caird Imogen,Martin Madhuri,Guillen Joyce,Eid Khalil T.,Aghajanian Carol,Makker Vicky

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference35 articles.

1. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study;Ozols;J. Clin. Oncol.,2003

2. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial;Katsumata;Lancet Oncol,2013

3. Randomized phase ill noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study;Miller;Gynecol. Oncol.,2012

4. XPO1/CRM1 inhibition causes antitumor effects by mitochondrial accumulation of eIF5A;Miyake;Clin. Cancer Res.,2015

5. Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian Cancer;Chen;Clin. Cancer Res.,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management;Frontiers in Immunology;2024-05-10

2. The nuclear export protein exportin‐1 in solid malignant tumours: From biology to clinical trials;Clinical and Translational Medicine;2024-05

3. Selinexor in patients with advanced and recurrent endometrial cancer;Current Problems in Cancer;2023-12

4. Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?;Med;2023-11

5. Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice;Cancers;2023-09-13